In weighing the risks of myocarditis versus the risks of COVID-19, one key difference between CDC’s modeling and FDA’s “worst-case” scenario is that CDC relied on VAERS, while FDA’s used Optum’s US claims database. • Source: Nielsen Hobbs
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
